Over the years, alemtuzumab has been used to treat lymphomas and leukemias, including T cell lymphomas, peripheral T cell lymphoma-not otherwise specified (PTCL-NOS), T cell prolymphocytic leukemia (T-PLL), cutaneous T cell lymphoma (CTCL) and adult T cell lymphoma/leukemia (ATLL) as well as B cell malignancies, such as B-cell non-Hodgkin's lymphoma (B-NHL) and B-cell chronic lymphocytic lymphoma (B-CLL)
A., Dunngalvin, G., Kern, T., Auwerx, J., Aebischer, P., & Rinsch, C
10.3390/antibiotics13060541 24 de BritoB
Waiting less than 30 minutes introduces competing substrates that reduce effective dose
For Tesofensine, the focus is squarely on powerful appetite suppression and subsequent weight loss, with secondary interests in neurological pathways related to food reward and mood